The University of Southampton
Warning! Your browser is out-of-date and not compatible with this website. Please download a new secure and faster browser to view this website correctly.
(023) 8059 2395

Professor Ali Tavassoli 

Professor of Chemical Biology

Professor Ali Tavassoli's photo
Related links

Ali Tavassoli is professor of chemical biology, whose research efforts are directed towards the discovery and development of protein-protein interaction inhibitors.

Tavassoli lab website

Ali Currently leads an interdisciplinary team of scientists whose efforts are focused on the development of novel chemical tools that enable new insight into the role of protein-protein interactions in cell biology, and as the starting point for new therapeutics.

The main focus of the Tavassoli lab is the identification of cyclic peptide inhibitors of protein-protein interaction using a genetically encoded high-throughput screening platform. Our goal is the development of compounds capable of disrupting the association and assembly of protein complexes. The compounds uncovered in our lab serve as valuable tools that allow better understanding of the role of individual protein-protein interactions in cells. These compounds also form the starting point for the development of therapeutic compounds that target key protein-protein interactions in disease. Our research group is focused on training scientists at the chemistry-biology interface, and using these interdisciplinary skills to help understand the fundamentals of cell biology and to develop new therapeutic agents.

Ali is currently Chair of the RSC's "Chemical Biology and Bioorganic Group", and an elected member of the RSC's "Chemistry and Biology Interface Division" council. Ali has won a number of awards during his career, including the European Association for Chemical and Molecular Sciences' medal for European Young Chemist (in 2008). 




Research interests

Ali Tavassoli's Publications and Citation Metrics

The main focus of the Tavassoli lab has been the establishment and utilization of a genetically encoded high-throughput screening platform for the identification of protein-protein interaction inhibitors. 

Some of the projects currently underway in the lab are highlighted below.

The first specific inhibitor of HIF-1α/HIF-1β protein-protein interaction

Miranda E. et al., Journal of the American Chemical Society, 2013, 135 (28), 10418-10425.

Asby D. J. et al., Molecular Biosystems, 2014, 10 (10), 2505-2508.

HIF-1 is the cellular sensor of oxygen, and a key protein in the adaptation and survival of cancer cells in the hypoxic tumour microenvironment. We have recently reported the first specific inhibitor of HIF1α/HIF-1β dimerization. The inhibitor was identified using our bacterial high-throughput screening platform, and was extensively characterized in vitro and in cells, and shown to inhibit hypoxia-response signaling in cells. We also demonstrated that the compound does not disrupt the dimerization of HIF-2α/HIF-1β in vitro and in cells.

This work has generated significant interest in the media, including the CRUK blog.

This work is funded by Cancer Research UK

The first example of a non-natural, biocompatible DNA-backbone linker (with Prof. Tom Brown)

Birts C.N. et al., Angewandte Chemie, 2014, 53 (9), 2362-2365.

Sanzone A.P. et al., Nucleic Acids research, 2012, 40 (20), 10567-10575.

El-Sagheer A.H. et al., Proceedings of the National Academy of Science, 2011, 108 (28), 11338-11343.

Current DNA synthesis methods do not allow the preparation of epigenetically modified DNA fragments larger than ~200 bases (methods such as PCR use enzymes that can not read epigenetic information, and so any epigenetic information incorporated at the oligonucleotide synthesis stage will be erased in the amplified, assembled DNA). We are therefore seeking to establish a chemical method for DNA ligation that would allow assembly of synthetic oligonucleotides by a purely chemical method. This would allow the synthesis of large oligonucleotides (genes and genomes) that contain epigenetic information, and provide a significant tool for the study of epigenetics.

A key requirement for the above is the biocompatibility of the resulting non-natural DNA linker in living systems. We have assesses the suitability of click-linked DNA for this purpose; modified bases were incorporated at the appropriate termini of oligonucleotides, and linked by click chemistry. We have recently shown that the resulting non-natural triazole linked (replacing the phosphodiester normally present in DNA) is fully biocompatible in E. coli and mammalian cells.

 This work is funded by the BBSRC and EPSRC.

The first inhibitor of CtBP homodimerization (with Dr. Jeremy Blaydes)

Birts C.N. et al., Chemical Science, 2013, 4 (8), 3046-3057.

C-termina binding proteins are transcriptional regulators that dimerize in response to increased NADH levels, and modulate the gene expression. We used our high-throughput screening platform to identify cyclic peptide inhibitors of CtBP dimerization, and used these sompounds to show metabolic regulation of cell cycle fidelity in cancer cells. This paper was featured on the cover of the journal Chemical Science.

This work is funded by Cancer Research UK and Breast Cancer Campaign.

Research group(s)

Chemical Biology, Diagnostics and Therapeutics

Key Publication(s)


Book Section(s)

Professor Ali Tavassoli
Chemistry University of Southampton Highfield Southampton SO17 1BJ

Room Number: 30/4049

Telephone: (023) 8059 2395

Share this profileFacebookGoogle+TwitterWeibo

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.